Finally, as the present study lacked baseline AD biomarkers data, our findings that weight loss in preclinical AD mainly occurs when both Aβ and tau pathology are present should be confirmed in studies with longer follow-up duration and longitudinal biomarker data. Here, MAPT is linked to Alzheimer disease.